Monitoring the Seroprevalence of Herpes Simplex Virus-1 Among Egyptian Hemodialysis Patients

Hemodialysis patients are at high risk for infections due to their compromised
immune systems. Herpes Simplex Virus (HSV) infections can lead to severe complications in
this population. Despite its clinical significance, comprehensive data on the seroprevalence
of HSV among hemodialysis patients are limited. Objective: This study aims to evaluate the
seroprevalence of HSV-1 among Egyptian hemodialysis patients. Methods: A cross-sectional study
was conducted with 218 participants (116 females and 102 males). Among these, 132 (60.6%)
were undergoing hemodialysis, while 86 (39.4%) had normal kidney function and were free
from HCV, CMV, and HIV infections. Serum samples were analyzed for IgG antibodies against
HSV-1. Statistical analyses were performed to determine HSV seroprevalence. Results: The study
observed a significantly higher prevalence of HSV-1-IgG antibodies in hemodialysis patients
(84.1%) compared to the control group (66.3%, P<0.01). Additionally, HSV-1-IgM positivity was
also higher in the hemodialysis group (41.6%) compared to the control group (32.6%, P<0.05).
These findings highlight the need for vigilant monitoring and preventive strategies for HSV
infections in hemodialysis patients.